Monday, October 14, 2019

The Game-Changing Potential of Targeting RNA with Small Molecules: More Than Turning the Undruggable...

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) Once considered impossible, targeting RNA with small molecules has the potential to be a game-changer. It’s convincing enough to industry veteran Michael...

WuXi AppTec Acquires Pharmapace to Enhance Biometrics Services for Clinical Development

Shanghai, China & San Diego, California May 6, 2019 - WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that it has acquired...

WuXi AppTec Announces Strong First-Quarter 2019 Results

WuXi AppTec Announces Strong First-Quarter 2019 Results Revenue RMB2,769 Million, up 29.3% Net Profit Attributable to Owners of the Company RMB386 Million, up 33.0% Year-Over-Year Diluted EPS RMB0.33, up 6.5% Year-Over-Year (SHANGHAI, April 30,...

WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer

SHANGHAI and AUSTIN, Texas, April 8, 2019 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H....

WuXi STA’s New Drug Product Manufacturing Facility Passes First European MPA GMP Inspection

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its new drug product manufacturing facility in Shanghai Pilot Free Trade Zone has passed its first GMP...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS